RxDoctor Payments Data

Alfredo Jimenez, MD

Cardiovascular Disease · Dallas, TXNPI 1932147246

Payments from drug & device makers

$621in general payments, 2019–2025

Across 41 payments — averaging $15.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$164
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$87
  • Medtronic$84
  • Johnson & Johnson$66
  • Pfizer$62
  • Tactile Systems Technology Inc$53
  • plus $104 from 6 others

What the payments were for

  • Food & beverage$59496%
  • Education$264%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$621 in reported general payments places this provider in the 20th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$193,177
Medicare patients
361
Services billed
1,671

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban261$323,677
EntrestoSacubitril/Valsartan84$104,316
JardianceEmpagliflozin38$49,726
FarxigaDapagliflozin Propanediol43$41,154
XareltoRivaroxaban25$24,312
VascepaIcosapent Ethyl13$8,875
Repatha SureclickEvolocumab13$8,249
Icosapent Ethyl15$6,584
Metoprolol Succinate154$2,171
Amlodipine-AtorvastatinAmlodipine/Atorvastatin13$2,040
Flecainide Acetate31$1,967
Atorvastatin Calcium150$1,644
Telmisartan30$1,626
Ezetimibe82$1,575
Losartan Potassium121$1,277

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$62$323,677261 claims
NovartisEntresto$16$104,31684 claims
Boehringer IngelheimJardiance$28$49,72638 claims
AstraZenecaFarxiga$14$41,15443 claims
Johnson & JohnsonXarelto$66$24,31225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →